Navigation Links
IDSA Proposes New Pathway For Antibiotic Approval
Date:3/8/2012

WASHINGTON, March 8, 2012 /PRNewswire-USNewswire/ -- Congress will consider a new drug approval pathway to encourage development of critically needed, lifesaving antibiotics as part of a strategy to address the public health crisis of antibiotic resistance. The Infectious Diseases Society of America (IDSA) proposed the new pathway, the "Special Population Limited Medical Use (SPLMU)" mechanism, to provide an important new approval option for companies interested in developing drugs to treat patients with serious infections where few or no treatment options exist.

IDSA submitted the proposal to the House Energy and Commerce Committee Subcommittee on Health today during a hearing on the U.S. Food and Drug Administration (FDA) Prescription Drug User Fee Act (PDUFA) reauthorization legislation. During the hearing, lawmakers will consider whether to incorporate within PDUFA pending legislation known as the Generating Antibiotic Incentives Now (GAIN) Act, which proposes incentives to address the dry antibiotic research and development (R&D) pipeline. PDUFA is considered one of the few must-pass bills this year in Congress.

"Antimicrobial resistance is unequivocally one of the world's greatest public health threats, and we've been sounding the alarm about it – and the lack of new antibiotics in development – for years," said Brad Spellberg, MD, co-chair of IDSA's Antimicrobial Availability Task Force. "This new mechanism provides the opportunity to address this public health crisis while there is still time to fix it."

The SPLMU mechanism streamlines the approval pathway and enables pharmaceutical companies to study SPLMU drugs in far fewer patients than currently is required, more rapidly, and at significantly less cost – because they are intended for more targeted use within a special population of patients who lack other treatment options. SPLMU designation reserves a drug for use in specific populations in which the benefits outweigh the risks, and encourages prudent use of the drug to slow the rate of resistance.

"The proposed SPLMU drug approval mechanism will bring critically needed innovation to the anti-infective pipeline, encouraging antibiotic development and lowering the hurdles to getting these critically needed drugs to patients who desperately need them," said Robert Guidos, vice president of public policy and government relations at IDSA. "In addition, we've designed it to foster antimicrobial stewardship, so these drugs will be used only when appropriate, extending their lifesaving power."

To read the rest of this press release, click here: www.idsociety.org/New_Pathway_for_Antibiotic_Approval/.


'/>"/>
SOURCE Infectious Diseases Society of America (IDSA)
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Proposes Lower Risk Classification, Special Controls for External Pacemakers
2. FDA Proposes Guidelines That Clarify Benefit-Risk Determinations for Medical Devices
3. FDA Proposes New Policy for Some Diagnostic and Radiology Devices
4. Valeant Pharmaceuticals Proposes to Acquire Cephalon, Inc. for $73 Per Share in Cash
5. Mangrove Partners Proposes Fully-Financed Dividend Recapitalization to Board of CPEX Pharmaceuticals, Inc.
6. FDA Proposes Withdrawal of Low Blood Pressure Drug
7. American Association for Homecare Proposes Strong Anti-Fraud Measures in Medicare, Applauds HHS Testimony Today That Pledges to "Stop Fraud Before it Starts"
8. ActivBiotics Proposes Development Strategy for Its Novel Rifamycin Antibiotics
9. Cancer Cure Coalition Proposes Major Changes at the FDA
10. New Gene Study of ADHD Points to Defects in Brain Signaling Pathways
11. Functional Brain Pathways Disrupted in Children with ADHD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... -- Dehaier Medical Systems Ltd. (NASDAQ: DHRM ... sells medical devices and wearable sleep respiratory products in ... agreement with Hongyuan Supply Chain Management Co., Ltd. (hereinafter ... 2016, to develop Dehaier,s new Internet medical technology business. ... leverage Hongyuan Supply Chain,s sales platform to reach Dehaier,s ...
(Date:6/24/2016)... LEXINGTON, Mass. , June 24, 2016   ... specialty pharmaceutical company developing innovative inhaled drugs, announced today ... when Russell Investments reconstituted its comprehensive set ... 2016. "This is an important milestone for ... "It will increase shareholder awareness of our progress in ...
(Date:6/23/2016)... Research and Markets has announced the addition of ... report to their offering. ... kidney failure, it replaces the function of kidneys by removing ... thus the treatment helps to keep the patient body,s electrolytes ... Increasing number of ESRD patients & substantial healthcare expenditure ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business ... to $12 an hour by 2020 and then adjusting it yearly to increase at the ... minimum wage, assure the wage floor does not erode again, and make future increases more ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB ... Decision Making in Emergency Medicine conference in Ponte Vedra Beach, FL. The awards ... in Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , “With ...
(Date:6/24/2016)... Vegas, Nevada (PRWEB) , ... June 24, 2016 ... ... Las Vegas client, The Grove Investment Group (TGIG), has initiated cultivation and processing ... Grove, in Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of ...
(Date:6/24/2016)... ... ... National recruitment firm Slone Partners is pleased to announce the ... as Vice President of North American Capital Sales at HTG Molecular . ... team in the commercialization of the HTG EdgeSeq system and associated reagents in North ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... induced pluripotent stem (iPS) cells and other difficult to transfect cells, announces its ... The PluriQ™ G9™ Gene Editing System is a complete system for ...
Breaking Medicine News(10 mins):